Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

被引：0

作者：

Heist, Rebecca Suk

Gandhi, Leena

Shapiro, Geoffrey

Rizvi, Naiyer A.

Burris, Howard A.

Bendell, Johanna C.

Baselga, Jose

Yerganian, Scott B.

Hsu, Karl

Ogden, Janet

Vincent, Loic

von Richter, Oliver

Locatelli, Giuseppe

Asatiani, Ekatherine

Infante, Jeffrey R.

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Tennessee Oncol, Nashville, TN USA

[6] Sanofi Aventis, Cambridge, MA USA

[7] EMD Serono Inc, Billerica, MA USA

[8] Sanofi Oncol, Vitry Sur Seine, France

[9] Merck KGaA, Darmstadt, Germany

[10] Merck Serono SA, Geneva, Switzerland

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2530

引用

页数：2